Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Overland Park, Kansas


Purpose:

This study is designed as a single ascending dose study in healthy subjects to evaluate safety, tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) in plasma and Cerebrospinal (CSF) following single oral doses of E2212.


Criteria:

Inclusion Criteria: 1. Healthy men and women of non-child bearing potential age 18 and 55 years old at the time of Screening; 2. Body mass index (BMI) 18 and 30 kg/m2 at Screening; 3. Are willing and able to comply with all aspects of the protocol; and 4. Provide written informed consent. Exclusion Criteria: 1. Clinically important abnormalities on physical examination, vital signs or clinical laboratories. 2. History of serious medical illness 3. Smoking or use of tobacco-containing products within past 3 months 4. History of alcohol or drug abuse within past 2 years


NCT ID:

NCT01221259


Primary Contact:

Principal Investigator
Philip Lee, Md
Quintiles Phase One Service


Backup Contact:

N/A


Location Contact:

Overland Park, Kansas
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.